This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study


Herrmann, Nathan, Binder, Carin, Dalziel, William, Smyth, Steve, Camacho, Fernando


Drugs & Aging, Volume: 26, No.: 5, Pages.: 403-407

Year of Publication



Objective: To determine if choice of drug and ease of administration affect persistence of therapy with cholinesterase inhibitors (ChEIs) for treatment of dementia.; Methods: An observational administrative health database study was conducted in 5622 patients aged >or=65 years who received a new prescription for donepezil (DON), rivastigmine (RIV) or galantamine (GAL) from February to May 2006. Patients were followed for 1 year from initiation of therapy to determine percentage persistence and days of therapy. Once-daily galantamine extended release (GAL-ER) was compared with twice-daily galantamine immediate release (GAL-IR) to determine if ease of administration affected persistence. Previous treatment with ChEIs was also documented.; Results: One-year persistence rates were significantly different among the ChEIs: GAL-ER 54% (95% CI 51, 57), DON 46% (95% CI 43, 49) and RIV 40% (95% CI 37, 43). Average days of therapy were greater for GAL-ER (293) than for RIV (272), but there were no differences between DON (287) and GAL-ER or DON and RIV. One-year persistence was significantly greater for GAL-ER 54% (95% CI 48, 59) than for GAL-IR 44% (95% CI 39, 50), although there was no significant difference in days of therapy (293 vs 286, respectively). More patients currently treated with RIV (40.5%) or GAL-ER (32.3%) had received previous treatment with a different ChEI than with DON (21.9%).; Conclusion: Among possible factors affecting persistence of ChEI therapy for dementia, choice of drug, ease of administration and previous treatment appear to be important.;

Bibtex Citation

@article{Herrmann_2009, doi = {10.2165/00002512-200926050-00004}, url = {}, year = 2009, month = {may}, publisher = {Springer Science $mathplus$ Business Media}, volume = {26}, number = {5}, pages = {403--407}, author = {Nathan Herrmann and Carin Binder and William Dalziel and Steve Smyth and Fernando Camacho}, title = {Persistence with Cholinesterase Inhibitor Therapy for Dementia}, journal = {Drugs {&} Aging} }


adherence, administration & dosage, aged, aged, 80 and over, alzheimer disease, cholinesterase inhibitors, databases factual, dementia, donepezil, drug therapy, etiology, galantamine, humans, indans, medication, medication adherence, phenylcarbamates, piperidines, statistics & numerical data, therapeutic use, to

Countries of Study


Types of Dementia

Dementia (general / unspecified)

Types of Study

Cohort Study, Cost and service use study

Type of Outcomes

Other, Service use or cost reductions (incl. hospital use reduction, care home admission delay)

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime